BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27957769)

  • 1. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.
    Zhou D; Xu L; Huang W; Tonn T
    Molecules; 2018 May; 23(6):. PubMed ID: 29857542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 7. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
    Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
    Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
    Stergiou N; Gaidzik N; Heimes AS; Dietzen S; Besenius P; Jäkel J; Brenner W; Schmidt M; Kunz H; Schmitt E
    Cancer Immunol Res; 2019 Jan; 7(1):113-122. PubMed ID: 30413430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S-configured Pam3 CysSerLys4.
    Shi L; Cai H; Huang ZH; Sun ZY; Chen YX; Zhao YF; Kunz H; Li YM
    Chembiochem; 2016 Aug; 17(15):1412-5. PubMed ID: 27188544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
    Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
    Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
    Glaffig M; Stergiou N; Schmitt E; Kunz H
    ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
    Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
    Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
    Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
    Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
    Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
    ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.